These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 11589267

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW.
    Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
    [Abstract] [Full Text] [Related]

  • 3. Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy.
    Carr MC, Knopp RH, Brunzell JD, Wheeler BS, Zhu X, Lakshmanan M, Rosen AS, Anderson PW.
    Diabetes Care; 2005 Jul; 28(7):1555-61. PubMed ID: 15983300
    [Abstract] [Full Text] [Related]

  • 4. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
    Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R, Sacristán J, Marín F.
    Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
    [Abstract] [Full Text] [Related]

  • 5. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.
    Cohen FJ, Lu Y.
    Maturitas; 2000 Jan 15; 34(1):65-73. PubMed ID: 10687884
    [Abstract] [Full Text] [Related]

  • 6. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D, Spencer CM.
    Drugs; 2000 Aug 15; 60(2):379-411. PubMed ID: 10983739
    [Abstract] [Full Text] [Related]

  • 7. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
    Palacios S, Farias ML, Luebbert H, Gomez G, Yabur JA, Quail DC, Turbi C, Kayath MJ, Almeida MJ, Mönnig E, Nickelsen T.
    Am J Obstet Gynecol; 2004 Jul 15; 191(1):121-31. PubMed ID: 15295352
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K.
    Osteoporos Int; 2003 Oct 15; 14(10):793-800. PubMed ID: 12955333
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
    Zheng S, Wu Y, Zhang Z, Yang X, Hui Y, Zhang Y, Chen S, Deng W, Liu H, Ekangaki A, Stocks J, Harper K, Liu J.
    Chin Med J (Engl); 2003 Aug 15; 116(8):1127-33. PubMed ID: 12935394
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
    Anderson PW, Cox DA, Sashegyi A, Paul S, Silfen SL, Walsh BW.
    Maturitas; 2001 Jul 25; 39(1):71-7. PubMed ID: 11451623
    [Abstract] [Full Text] [Related]

  • 17. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
    Goldstein SR, Bhattoa HP, Neven P, Cox DA, Dowsett SA, Alam J, Sipos A, Muram D.
    Menopause; 2012 Jan 25; 19(1):41-7. PubMed ID: 21993078
    [Abstract] [Full Text] [Related]

  • 18. Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women.
    Cox DA, Sarkar S, Harper K, Barrett-Connor E.
    Curr Med Res Opin; 2004 Jul 25; 20(7):1049-55. PubMed ID: 15265250
    [Abstract] [Full Text] [Related]

  • 19. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
    Lee WL, Cheng MH, Tarng DC, Yang WC, Lee FK, Wang PH.
    J Chin Med Assoc; 2013 Jul 25; 76(7):365-71. PubMed ID: 23664736
    [Abstract] [Full Text] [Related]

  • 20. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
    Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD, MORE Investigators (Multiple Outcomes of Raloxifene Evaluation).
    JAMA; 2002 Feb 20; 287(7):847-57. PubMed ID: 11851576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.